Phase 1 N=10 Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)
Type 2 Diabetes Mellitus
Primary: Recovery Time From Hypoglycemia to Euglycemia — 74.49; 88.90; 109.81 Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension
Healthy Volunteers
Primary: The Area Under the Serum Concentration Curve (AUC) During 72 Hours After Dose (AUC72h) During Fasting Conditions. — 403; 346 uM*h
Phase 1 N=40 Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1 — 26.5; 31.6; 3.8; -2.3 pmol/L*hr — p=0.388
Phase 1 N=66 Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Impaired Renal Function
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 445892.7; 932688.3; 1531185.8; 1261081.6 ng*hr/ml
Phase 1 N=32 A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
Hepatitis C
Primary: Maximum Observed Plasma Concentration (Cmax): Day 1 — 3467.0; 27437.1; 23046.7; 48392.6 nanogram per milliliter (ng/mL)
Phase 1 N=98 A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Postoperative Nausea and Vomiting
Primary: Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1 — 5.97; 4.76; 6.16; 6.01 hr*ug/ml
Phase 1 N=780 Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
Influenza
Primary: Number of Seroconverted Subjects Against the A/Indonesia/5/2005 (H5N1) Strain of Influenza Disease. — 13; 140; 131; 135 Participants
Phase 1 N=3 Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)
Alzheimer's Disease
Primary: Number of Participants With an Adverse Event (AE) — 8 participants
Phase 1 N=72 Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
Rheumatoid Arthritis
Primary: Maximum Observed Concentration (Cmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population — 262; 255 µg/mL
Phase 1 N=29 Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Graft Versus Host Disease
Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day
Phase 1 N=12 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Phase 1 N=48 The Effect of Palatal Brushing on Denture Stomatitis
Denture Stomatitis
Primary: Palatal Inflammation — 3; 3; 2.5; 2 units on a scale — p=<0.0001
Phase 1 N=41 A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 11; 11; 6 Participants
Phase 1 N=22 A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)
Type 2 Diabetes Mellitus
Primary: Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough — 91.73; 73.50; 28.88; 90.63 Percent inhibition — p=<.001
Phase 1 N=127 Study of the Mechanisms of Asthma
Asthma
Primary: Gene Expression in Airway Secretions and Tissues — -0.66; 0.54; -0.30 Relative gene expression level